Risk-Reduction Therapy: The Challenge to Change. Presented at the 68th Scientific Sessions of the American Heart Association November 13, 1995 Anaheim, California

Circulation

Volumn 93, Issue 12, 1996, Pages 2205-2211

  Smith Jr , Sdney C ^a  

^a AMERICAN HEART ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CORONARY RISK; HEALTH CARE COST; HEALTH CARE POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK MANAGEMENT; UNITED STATES;

ANTILIPEMIC AGENTS; CARDIOLOGY; CARDIOVASCULAR DISEASES; HUMANS; LIFE STYLE; RISK FACTORS; SMOKING; UNITED STATES;

EID: 0029885631     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.12.2205     Document Type: Conference Paper

References (41)

1. Moore WW. Fighting for Life: The Story of the American Heart Association, 1911-1975. Dallas, Tex: American Heart Association; 1983.
2. The American Heart Association Bulletin. November 1925;1(2).
3. Heart and Stroke Facts: 1995 Statistical Supplement. Dallas, Tex: American Heart Association; 1995.
4. Pyorala K. Changing coronary heart disease trends in Europe: implications for prevention: Geoffrey Rose Memorial Lecture. Presented at the European Society of Cardiology Meeting; August 1995; Amsterdam, Netherlands.
5. Lynch J, Kaplan GA, Salonen R, Cohen RD, Salonen JT. Socioeconomic status and carotid atherosclerosis. Circulation. 1995;92: 1786-1792.
6. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
7. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355-1374.
8. Fuster V, Lewis A. Connor Memorial Lecture: mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
9. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
10. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994;23:809-813.
11. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1995;332:512-521.
12. Philbin EF, Pearson TA. How does lipid-lowering therapy rapidly reduce ischemic events? J Myocard Ischemia. 1994;6:13-18.
13. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, McGovern ME, for the PLAC I investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26: 1133-1139.
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
15. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90: 1679-1687.
16. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-677.
17. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
18. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
19. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, Braunwald E. Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement trial. Circulation. 1994;90:1731-1738.
20. Cohen MV, Byrne MJ, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 1991;83:1294-1304.
21. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, Krumholz HM, Vogel RA. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273: 1509-1514.
22. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
23. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heurt J. 1994;15:1300-1331.
24. Parish S, Collins R, Peto R, Youngman L, Barton J, Jayne K, Clarke R, Appleby P, Lyon V, Cederholm-Williams S, Marshall J, Sleight P, for the ISIS Collaborators. Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14,000 cases and 32,000 controls in the United Kingdom. BMJ. 1995;311:471-477.
25. Mortality from Smoking in Developed Countries, 1950-2000: Indirect Estimates from National Vital Statistics. New York, NY: Oxford University Press; 1994:A-74.
26. Bartecchi CE, MacKenzie TD, Schrier RW. The human costs of tobacco use. N Engl J Med. 1994;330:907-912,975-980.
27. Secondary prevention of vascular disease by prolonged antiplatelet treatment: Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed). 1988;296:320-331.
28. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990; 323:147-152.
29. Garcia-Dorado D, Theroux P, Tornos P, Sambola A, Oliveras J, Santos M, Soler JS. Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes. Circulation. 1995;92:1743-1748.
30. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
31. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, Platt R. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-1131.
32. Patient Compliance: Lipid Lowering Agents TOP Study. Merck & Co, Inc; 1992.
33. Gillum RF, Neutra RR, Stason WB, Solomon HS. Determinants of dropout rate among hypertensive patients in an urban clinic. J Community Health. 1979;5:94-100.
34. Wirebaugh SR, Whitney EJ. Long-term compliance with lipid-lowering therapy. Pharmacol Ther. 1993;18:559-71.
35. DeBusk RF, Miller NH, Superko HR, Dennis CA, Thomas RJ, Lew HT, Berger WE III, Heller RS, Rompf J, Gee D, Kraemer HC, Bandura A, Ghandour G, Clark M, Shah RV, Fisher L, Taylor CB. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120: 721-729.
36. Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR, Kuntz KM, Lee TH. Cost effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol. 1995;26:914-919.
37. Gaspoz JM, Goldman P, Williams L, Weinstein M, Goldman L. Cost-effectiveness of aspirin in secondary prevention of coronary heart disease. Circulation. 1995;92(suppl I):I-47. Abstract.
38. Glick H, Cook J, Pitt B, Kinosian B, Bourassa M, Pouleur H, Gerth W. The cost and benefits of enalapril therapy in post-MI patients with asymptomatic left ventricular dysfunction. Circulation. 1995; 92(suppl I):I-510. Abstract.
39. Schwartz JS, Kjekshus J, Pedersen TR. Impact of cholesterol lowering on resource use and cost among patients with coronary heart disease (CHD): results from 4S. Circulation. 1995;92(suppl I):I-510. Abstract.
40. Addison T, Gull W. On a certain affection of the skin Vitiligoidea - α. Plana, β. Tuberosa. Guy's Hospital Gazette. 1851;7:265-276.
41. White PD. The tardy growth of preventive cardiology. Am J Cardiol. 1972;29:886-888.